{
    "references": [
        {
            "bibentry": "Xue, ST, Guo, F, Liu, MJ, et al. Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats. Eur J Med Chem 2015; 96: 151–61. PMID: 25874339",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2015.04.016",
            "pmid": "25874339",
            "xmlid": "CIT0001"
        },
        {
            "bibentry": "Lin, QJ, Yang, F, Jin, C, Fu, D. Current status and progress of pancreatic cancer in China. World J Gastroenterol 2015; 21: 7988–8003. PMID: 26185370",
            "process_entry": "True",
            "doi": "10.3748/wjg.v21.i26.7988",
            "pmid": "26185370",
            "pmcid": "PMC4499341",
            "xmlid": "CIT0002"
        },
        {
            "bibentry": "Appelbaum, PC, Hunter, PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents 2000; 16: 5–15. PMID: 11185413",
            "process_entry": "True",
            "doi": "10.1016/s0924-8579(00)00192-8",
            "pmid": "11185413",
            "xmlid": "CIT0003"
        },
        {
            "bibentry": "Frere, JM. Beta-lactamases and bacterial resistance to antibiotics. Mol Microbial 1995; 16: 385–95.",
            "process_entry": "True",
            "xmlid": "CIT0004"
        },
        {
            "bibentry": "Devasahayam, G, Scheld, WM, Hoffman, PS. Newer antibacterial drugs for a new century. Expert Opin Invest Drugs 2010; 19: 215–34.",
            "process_entry": "True",
            "xmlid": "CIT0005"
        },
        {
            "bibentry": "Settimo, AD, Settimo, FD, Marini, AM, et al. Synthesis, DNA binding and in vitro antiproliferative activity of purinoquinazoline, pyridopyrimidopurine and pyridopyrimidobenzimidazole derivatives as potential antitumor agents. Eur J Med Chem 1998; 33: 685–96.",
            "process_entry": "True",
            "xmlid": "CIT0006"
        },
        {
            "bibentry": "Sondhi, SM, Singh, J, Rani, R, et al. Synthesis, anti-inflammatory and anticancer activity evaluation of some novel acridine derivatives. Eur J Med Chem 2010; 45: 555–63. PMID: 19926172",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2009.10.042",
            "pmid": "19926172",
            "xmlid": "CIT0007"
        },
        {
            "bibentry": "Sano, H, Noguchi, T, Tanatani, A, et al. Design and synthesis of subtype-selective cyclooxygenase (COX) inhibitors derived from thalidomide. Bioorg Med Chem 2005; 13: 3079–91. PMID: 15809144",
            "process_entry": "True",
            "doi": "10.1016/j.bmc.2005.03.002",
            "pmid": "15809144",
            "xmlid": "CIT0008"
        },
        {
            "bibentry": "Hashimoto, Y. Thalidomide as a multi-template for development of biologically active compounds. Arch Pharm (Weinheim) 2008; 341: 536–47. PMID: 18389516",
            "process_entry": "True",
            "doi": "10.1002/ardp.200700217",
            "pmid": "18389516",
            "xmlid": "CIT0009"
        },
        {
            "bibentry": "Lamie, PF, Philoppes, JN, El-Gendy, AO, et al. Design, synthesis and evaluation of novel phthalimide derivatives as in vitro anti-Microbial, anti-Oxidant and anti-inflammatory agents. Molecules 2015; 20: 16620–42. PMID: 26389864",
            "process_entry": "True",
            "doi": "10.3390/molecules200916620",
            "pmid": "26389864",
            "pmcid": "PMC6331814",
            "xmlid": "CIT0010"
        },
        {
            "bibentry": "Zahra, R, Setareh, M, Rezvan, J, et al. Synthesis and biological evaluation of 1,3,4-thiadiazole linked phthalimide derivatives as anticancer agents. Lett Drug Des Discov 2017; 14: 1138–44.",
            "process_entry": "True",
            "xmlid": "CIT0011"
        },
        {
            "bibentry": "Stewart, SG, Spagnolo, D, Polomska, ME, et al. Synthesis and TNF expression inhibitory properties of new thalidomide analogues derived via Heck cross coupling. Bioorg Med Chem Lett 2007; 17: 5819–24. PMID: 17851074",
            "process_entry": "True",
            "doi": "10.1016/j.bmcl.2007.08.042",
            "pmid": "17851074",
            "xmlid": "CIT0012"
        },
        {
            "bibentry": "Noguchi, T, Fujimoto, H, Sano, H, et al. Angiogenesis inhibitors derived from thalidomide. Bioorg Med Chem Lett 2005; 15: 5509–13. PMID: 16183272",
            "process_entry": "True",
            "doi": "10.1016/j.bmcl.2005.08.086",
            "pmid": "16183272",
            "xmlid": "CIT0013"
        },
        {
            "bibentry": "Amin, KM, El-masry, AH, Mohamed, NA, et al. Synthesis, characterization and anti-microbial activity of some novel isoindole-1,3-dione derivatives. Der Pharm Chem 2013; 5: 97–108.",
            "process_entry": "True",
            "xmlid": "CIT0014"
        },
        {
            "bibentry": "Meng, XB, Han, D, Zhang, SN, et al. Synthesis and antiinflammatory activity of N-phthalimidomethyl 2,3-dideoxy-and 2,3-unsaturated glycosides. Carbohydr Res 2007; 342: 1169–74. PMID: 17407773",
            "process_entry": "True",
            "doi": "10.1016/j.carres.2007.03.009",
            "pmid": "17407773",
            "xmlid": "CIT0015"
        },
        {
            "bibentry": "Nossier, ES, Fahmy, HH, Khalifa, NM, et al. Design and synthesis of novel pyrazole-substituted different nitrogenous heterocyclic ring systems as potential anti-inflammatory agents. Molecules 2017; 22: 512.",
            "process_entry": "True",
            "xmlid": "CIT0016"
        },
        {
            "bibentry": "El Shehry, MF, Ghorab, MM, Abbas, SY, et al. Quinoline derivatives bearing pyrazole moiety: synthesis and biological evaluation as possible antibacterial and antifungal agents. Eur J Med Chem 2018; 143: 1463–73. PMID: 29113746",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2017.10.046",
            "pmid": "29113746",
            "xmlid": "CIT0017"
        },
        {
            "bibentry": "Sharath, V, Kumar, HV, Naik, N. Synthesis of novel indole based scaffolds holding pyrazole ring as anti-inflammatory and antioxidant agents. J Pharm Res 2013; 6: 785–90.",
            "process_entry": "True",
            "xmlid": "CIT0018"
        },
        {
            "bibentry": "Abdallah, MA, Gomha, SM, Abbas, IM, et al. An efficient synthesis of novel pyrazole-based heterocycles as potential antitumor agents. Appl Sci 2017; 7: 785.",
            "process_entry": "True",
            "xmlid": "CIT0019"
        },
        {
            "bibentry": "Lv, XH, Li, QS, Ren, ZL, et al. (E)-1,3-diphenyl-1H-pyrazole derivatives containing O-benzyl oxime moiety as potential immunosuppressive agents: design, synthesis, molecular docking and biological evaluation. Eur J Med Chem 2016; 108: 586–93. PMID: 26720154",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2015.12.020",
            "pmid": "26720154",
            "xmlid": "CIT0020"
        },
        {
            "bibentry": "Grosse, S, Mathieu, V, Pillard, C, et al. New imidazo[1,2-b]pyrazoles as anticancer agents: synthesis, biological evaluation and structure activity relationship analysis. Eur J Med Chem 2014; 84: 718–30. PMID: 25064349",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2014.07.057",
            "pmid": "25064349",
            "xmlid": "CIT0021"
        },
        {
            "bibentry": "(a) Elleder, D, Young, JAT, Baiga, TJ, Noel, JP. WO 2009061856. Chem Abstr 2009; 2009: 531249 (b), Frey, B, Hufton, R, Harding, M, Draffan, AG. WO 2013036994. Chem Abstr 2013; 2013: 446979.",
            "process_entry": "True",
            "xmlid": "CIT0022"
        },
        {
            "bibentry": "Ismail, NSM, Ali, GME, Ibrahim, DA, Elmetwal, AM. Medicinal attributes of pyrazolo[1,5-a]pyrimidine based scaffold derivatives targeting kinases as anticancer agents. Future J Pharm Sci 2016; 2: 60–70.",
            "process_entry": "True",
            "xmlid": "CIT0023"
        },
        {
            "bibentry": "Griffith, DA, Hargrove, DM, Maurer, TS, et al. Discovery and evaluation of pyrazolo[1,5-a]pyrimidines as neuropeptide Y1 receptor antagonist. Bioorg Med Chem Lett 2011; 21: 2641–5. PMID: 21295475",
            "process_entry": "True",
            "doi": "10.1016/j.bmcl.2010.12.116",
            "pmid": "21295475",
            "xmlid": "CIT0024"
        },
        {
            "bibentry": "Lim, FPL, Dolzhenko, AV. 1,3,5-Triazine-based analogues of purine: from isosteres to privileged scaffolds in medicinal chemistry. Eur J Med Chem 2014; 85: 371–90. PMID: 25105925",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2014.07.112",
            "pmid": "25105925",
            "xmlid": "CIT0025"
        },
        {
            "bibentry": "Smolnikov, SA, Gorgopina, EV, Lezhnyova, VR, et al. 4-Phenethylthio-2-phenylpyrazolo[1,5-a][1,3,5]triazin-7(6 H)-one. Molbank 2017; 2017: M970.",
            "process_entry": "True",
            "xmlid": "CIT0026"
        },
        {
            "bibentry": "Gad-Elkareem, MAM, Othman, I. Synthesis, reactions and biological evaluation of novel 7-thioxopyrido [2,3-d][1,2,3]triazine derivatives bearing sulfonamide moiety. Inter J Adv Res 2016; 4: 1689–700.",
            "process_entry": "True",
            "xmlid": "CIT0027"
        },
        {
            "bibentry": "Elzahabi, HSA, Nossier, ES, Khalifa, NM, et al. Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido[2,3-d]pyrimidine scaffold. J Enzyme Inhibition Med Chem 2018; 33: 546–57.",
            "process_entry": "True",
            "xmlid": "CIT0028"
        },
        {
            "bibentry": "Gad-Elkareem, MAM, Othman, I. Synthesis and antimicrobial evaluation of some new thienopyrazoles, pyrazolothienopyridines and pyrazolothienopyrimidines via Gewald reaction. Int J Pharma Sci 2017; 7: 1808–16.",
            "process_entry": "True",
            "xmlid": "CIT0029"
        },
        {
            "bibentry": "Gad-Elkareem, MAM, Abdel-Fattah, AM, Elneairy, M. Pyrazolo[3,4-b]-pyridine in heterocyclic synthesis: synthesis of new pyrazolo[3,4-b]-pyridines, imidazo[1',2':1,5]pyrazolo[3,4-b]pyridines, and pyrido[2',3':3,4]pyrazolo-[1,5-a]-pyrimidines. Can J Chem 2007; 85: 592–9.",
            "process_entry": "True",
            "xmlid": "CIT0030"
        },
        {
            "bibentry": "Gad-Elkareem, MAM, Abdel-Fattah, AM, Elneairy, M. Pyridine-2(1 H)-thione in heterocyclic synthesis: synthesis and antimicrobial activity of some new thiosubstituted ethyl nicotinate, thieno[2,3-b]pyridine and pyridothieno-pyrimidine derivatives. J Sulfur Chem 2011; 32: 273–86.",
            "process_entry": "True",
            "xmlid": "CIT0031"
        },
        {
            "bibentry": "Gad-Elkareem, MAM, El-Adasy, AA. Synthesis and antibacterial activity of some new ethyl thionicotinates, thieno[2,3-b]pyridines, pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidines, and pyrido[3′,2′:4,5]thieno[3,2-d]-[1,2,3]triazines containing sulfonamide moieties. Phosphorus Sulfur Silicon Relat Elem 2010; 185: 411–21.",
            "process_entry": "True",
            "xmlid": "CIT0032"
        },
        {
            "bibentry": "Zahran, M, Agwa, H, Osman, A, et al. Synthesis and biological evaluation of phthalimide dithiocarbamate and dithioate derivatives as anti-proliferative and anti-angiogenic agents-I. Eur J Med Chem 2017; 8: 391–9.",
            "process_entry": "True",
            "xmlid": "CIT0033"
        },
        {
            "bibentry": "Cardoso, MVO, Moreira, DRM, Filho, GBO, et al. Design, synthesis and structure activity relationship of phthalimides endowed with dual antiproliferative and immunomodulatory activities. Eur J Med Chem 2015; 96: 491–503. PMID: 25942060",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2015.04.041",
            "pmid": "25942060",
            "xmlid": "CIT0034"
        },
        {
            "bibentry": "Ahmed, HEA, Abdel-Salam, HA, Shaker, MA. Synthesis, characterization, molecular modeling, and potential antimicrobial and anticancer activity of novel 2-aminoisoindoline-1,3-dione derivatives. Bioorg Chem 2016; 66: 1–11. PMID: 26986635",
            "process_entry": "True",
            "doi": "10.1016/j.bioorg.2016.03.003",
            "pmid": "26986635",
            "xmlid": "CIT0035"
        },
        {
            "bibentry": "Zahran, MAH, El-Aarag, B, Mehany, ABM, et al. Design, synthesis, biological evaluations, molecular docking, and in vivo studies of novel phthalimide analogs. Arch Pharm Chem Life Sci 2018; 351: 1700363.",
            "process_entry": "True",
            "xmlid": "CIT0036"
        },
        {
            "bibentry": "Ibrahim, HS, Eldehna, WM, Abdel-Aziz, HA, et al. Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2 H)-one scaffolds. Eur J Med Chem 2014; 85: 480–6. PMID: 25113876",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2014.08.016",
            "pmid": "25113876",
            "xmlid": "CIT0037"
        },
        {
            "bibentry": "Vijayan, P, Raghu, C, Ashok, G, et al. Antiviral activity of medicinal plants of Nilgiris. Indian J Med Res 2004; 120: 24–9. PMID: 15299228",
            "process_entry": "True",
            "pmid": "15299228",
            "xmlid": "CIT0038"
        },
        {
            "bibentry": "Mosmann, T. Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assays. J Immuol Methods 1983; 65: 55–63.",
            "process_entry": "True",
            "xmlid": "CIT0039"
        },
        {
            "bibentry": "Maxwell, A, Burton, NP, O'Hagan, N. High-throughput assays for DNA gyrase and other topoisomerases. Nucleic Acids Res 2006; 34: e104. PMID: 16936317",
            "process_entry": "True",
            "doi": "10.1093/nar/gkl504",
            "pmid": "16936317",
            "pmcid": "PMC1616945",
            "xmlid": "CIT0040"
        },
        {
            "bibentry": "Amr, AE, Abo-Ghalia, MH, Moustafa, G, et al. Design, synthesis and docking studies of novel macrocyclic pentapeptides as anticancer multi-targeted kinase inhibitors. Molecules 2018; 23: 2416.",
            "process_entry": "True",
            "xmlid": "CIT0041"
        },
        {
            "bibentry": "Zhao, YH, Abraham, MH, Le, J, et al. Rate-limited steps of human oral absorption and QSAR studies. Pharm Res 2002; 19: 1446–57. PMID: 12425461",
            "process_entry": "True",
            "doi": "10.1023/a:1020444330011",
            "pmid": "12425461",
            "xmlid": "CIT0042"
        },
        {
            "bibentry": "Paramashivam, SK, Elayaperumal, K, Natarajan, BB, et al. In silico pharmacokinetic and molecular docking studies of small molecules derived from Indigofera aspalathoides Vahl targeting receptor tyrosine kinases. Bioinformation 2015; 11: 73–84. PMID: 25848167",
            "process_entry": "True",
            "doi": "10.6026/97320630011073",
            "pmid": "25848167",
            "pmcid": "PMC4369682",
            "xmlid": "CIT0043"
        },
        {
            "bibentry": "Veber, DF, Johnson, SR, Cheng, H, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002; 45: 2615–23. PMID: 12036371",
            "process_entry": "True",
            "doi": "10.1021/jm020017n",
            "pmid": "12036371",
            "xmlid": "CIT0044"
        },
        {
            "bibentry": "Lafitte, D, Lamour, V, Tsvetkov, PO, et al. DNA gyrase interaction with coumarin-based inhibitors: the role of the hydroxybenzoate isopentenyl moiety and the 5'-methyl group of the noviose. Biochem 2002; 41: 7217–23. PMID: 12044152",
            "process_entry": "True",
            "doi": "10.1021/bi0159837",
            "pmid": "12044152",
            "xmlid": "CIT0045"
        },
        {
            "bibentry": "Hasegawa, M, Nishigaki, N, Washio, Y, et al. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors. J Med Chem 2007; 50: 4453–70. PMID: 17676829",
            "process_entry": "True",
            "doi": "10.1021/jm0611051",
            "pmid": "17676829",
            "xmlid": "CIT0046"
        },
        {
            "bibentry": "Amr, AE, Elsayed, EA, Al-Omar, MA, et al. Design, synthesis, anticancer evaluation and molecular modeling of novel estrogen derivatives. Molecules 2019; 24: 416.",
            "process_entry": "True",
            "xmlid": "CIT0047"
        },
        {
            "bibentry": "Dey, SK, Lightner, DA. 1,1'-bipyrroles: synthesis and stereochemistry. J Org Chem 2007; 72: 9395–7. PMID: 17958450",
            "process_entry": "True",
            "doi": "10.1021/jo7016789",
            "pmid": "17958450",
            "pmcid": "PMC2655109",
            "xmlid": "CIT0048"
        },
        {
            "bibentry": "Saleh, MA, Abdel-Megeed, MF, Abdo, MA, Shokr, AM. Synthesis of novel 3 H-quinazolin-4-ones containing pyrazolinone, pyrazole and pyrimidinone moieties. Molecules 2003; 8: 363–73.",
            "process_entry": "True",
            "xmlid": "CIT0049"
        },
        {
            "bibentry": "Gouda, MA, Berghot, MA, Shoeib, AI, Khalil, AM. Synthesis and antimicrobial of new anthraquinone derivatives incorporating pyrazole moiety. Eur J Med Chem 2010; 45: 1843–8. PMID: 20144494",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2010.01.021",
            "pmid": "20144494",
            "xmlid": "CIT0050"
        },
        {
            "bibentry": "Bickerton, GR, Paolini, GV, Besnard, J, et al. Quantifying the chemical beauty of drugs. Nat Chem 2012; 4: 90–8. PMID: 22270643",
            "process_entry": "True",
            "doi": "10.1038/nchem.1243",
            "pmid": "22270643",
            "pmcid": "PMC3524573",
            "xmlid": "CIT0051"
        },
        {
            "bibentry": "Ali, R, Siddiqui, N. New benzo[ d]thiazol-2-yl-aminoacetamides as potential anticonvulsants: synthesis, activity and prediction of molecular properties. Arch Pharm (Weinheim) 2015; 348: 254–65. PMID: 25782176",
            "process_entry": "True",
            "doi": "10.1002/ardp.201400466",
            "pmid": "25782176",
            "xmlid": "CIT0052"
        },
        {
            "bibentry": "Lipinski, CA, Lombardo, F, Dominy, BW, Feeney, PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 1997; 23: 3–25.",
            "process_entry": "True",
            "xmlid": "CIT0053"
        },
        {
            "bibentry": "Jarrahpour, A, Fathi, J, Mimouni, M, et al. Petra, Osiris and Molinspiration (POM) together as a successful support in drug design: antibacterial activity and biopharmaceutical characterization of some azo Schiff bases. Med Chem Res 2012; 21: 1984–90.",
            "process_entry": "True",
            "xmlid": "CIT0054"
        }
    ],
    "localid": "MED-31287341",
    "doi": "10.1080/14756366.2019.1637861",
    "pmid": "10.1080/14756366.2019.1637861",
    "pmcid": "31287341",
    "curator": "BEE EuropeanPubMedCentralProcessor",
    "source_provider": "Europe PubMed Central",
    "source": "https://www.ebi.ac.uk/europepmc/webservices/rest/31287341/fullTextXML",
    "reference_pointers": [
        [
            {
                "n_rp": 3,
                "xref_id": "CIT0001",
                "rp_string": "1–3",
                "pl_string": "1–3",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1,102)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 1,
                "xref_id": "",
                "pl_string": "1–3",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1,102)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 2,
                "xref_id": "",
                "pl_string": "1–3",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1,102)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 3,
                "xref_id": "CIT0001",
                "rp_string": "1–3",
                "pl_string": "1–3",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1,102)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 4,
                "xref_id": "CIT0004",
                "rp_string": "4",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),105,222)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 5,
                "xref_id": "CIT0006",
                "rp_string": "6",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),329,150)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 6,
                "xref_id": "CIT0008",
                "rp_string": "8",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,208)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 7,
                "xref_id": "CIT0009",
                "rp_string": "9",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),211,206)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 8,
                "xref_id": "CIT0011",
                "rp_string": "11",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),419,207)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Thalidomide is known as a multi-target drug that affects several cellular processes, including peptidase inhibition, (cyclooxygenase) COX inhibition, glucosidase inhibition and androgen receptor antagonism8. Research studies on the structure activity relationship (SAR) of the metabolites and analogues of thalidomide have revealed that the phthalimide ring system is an essential pharmacophoric fragment9,10. Phthalimide (isoindoline-1,3-dione) has usually been employed in the design of potential antitumour11, immunomodulatory12, antiangiogenic13, anti-microbial14 and anti-inflammatory15 drug candidates. Further, heterocyclic hits are of considerable utility in synthetic medicines or pesticides and biochemical effects. Heterocycles containing pyrazole, imidazo[1,2-b]-pyrazole, pyrazolopyrimidine, pyrazolo-triazine scaffolds exhibit versatile biological properties such as anti-inflammatory, antifungal, antioxidant, antitumor and immunosuppressive agents16–26. Hence, molecular hybridization strategy via introduction of different pharmacophoric fragments might improve the biological activity of phthalimide derivatives.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 9,
                "xref_id": "CIT0012",
                "rp_string": "12",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),419,207)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Thalidomide is known as a multi-target drug that affects several cellular processes, including peptidase inhibition, (cyclooxygenase) COX inhibition, glucosidase inhibition and androgen receptor antagonism8. Research studies on the structure activity relationship (SAR) of the metabolites and analogues of thalidomide have revealed that the phthalimide ring system is an essential pharmacophoric fragment9,10. Phthalimide (isoindoline-1,3-dione) has usually been employed in the design of potential antitumour11, immunomodulatory12, antiangiogenic13, anti-microbial14 and anti-inflammatory15 drug candidates. Further, heterocyclic hits are of considerable utility in synthetic medicines or pesticides and biochemical effects. Heterocycles containing pyrazole, imidazo[1,2-b]-pyrazole, pyrazolopyrimidine, pyrazolo-triazine scaffolds exhibit versatile biological properties such as anti-inflammatory, antifungal, antioxidant, antitumor and immunosuppressive agents16–26. Hence, molecular hybridization strategy via introduction of different pharmacophoric fragments might improve the biological activity of phthalimide derivatives.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 10,
                "xref_id": "CIT0013",
                "rp_string": "13",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),419,207)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Thalidomide is known as a multi-target drug that affects several cellular processes, including peptidase inhibition, (cyclooxygenase) COX inhibition, glucosidase inhibition and androgen receptor antagonism8. Research studies on the structure activity relationship (SAR) of the metabolites and analogues of thalidomide have revealed that the phthalimide ring system is an essential pharmacophoric fragment9,10. Phthalimide (isoindoline-1,3-dione) has usually been employed in the design of potential antitumour11, immunomodulatory12, antiangiogenic13, anti-microbial14 and anti-inflammatory15 drug candidates. Further, heterocyclic hits are of considerable utility in synthetic medicines or pesticides and biochemical effects. Heterocycles containing pyrazole, imidazo[1,2-b]-pyrazole, pyrazolopyrimidine, pyrazolo-triazine scaffolds exhibit versatile biological properties such as anti-inflammatory, antifungal, antioxidant, antitumor and immunosuppressive agents16–26. Hence, molecular hybridization strategy via introduction of different pharmacophoric fragments might improve the biological activity of phthalimide derivatives.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 11,
                "xref_id": "CIT0014",
                "rp_string": "14",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[7]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),419,207)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Thalidomide is known as a multi-target drug that affects several cellular processes, including peptidase inhibition, (cyclooxygenase) COX inhibition, glucosidase inhibition and androgen receptor antagonism8. Research studies on the structure activity relationship (SAR) of the metabolites and analogues of thalidomide have revealed that the phthalimide ring system is an essential pharmacophoric fragment9,10. Phthalimide (isoindoline-1,3-dione) has usually been employed in the design of potential antitumour11, immunomodulatory12, antiangiogenic13, anti-microbial14 and anti-inflammatory15 drug candidates. Further, heterocyclic hits are of considerable utility in synthetic medicines or pesticides and biochemical effects. Heterocycles containing pyrazole, imidazo[1,2-b]-pyrazole, pyrazolopyrimidine, pyrazolo-triazine scaffolds exhibit versatile biological properties such as anti-inflammatory, antifungal, antioxidant, antitumor and immunosuppressive agents16–26. Hence, molecular hybridization strategy via introduction of different pharmacophoric fragments might improve the biological activity of phthalimide derivatives.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 12,
                "xref_id": "CIT0015",
                "rp_string": "15",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[8]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),419,207)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Thalidomide is known as a multi-target drug that affects several cellular processes, including peptidase inhibition, (cyclooxygenase) COX inhibition, glucosidase inhibition and androgen receptor antagonism8. Research studies on the structure activity relationship (SAR) of the metabolites and analogues of thalidomide have revealed that the phthalimide ring system is an essential pharmacophoric fragment9,10. Phthalimide (isoindoline-1,3-dione) has usually been employed in the design of potential antitumour11, immunomodulatory12, antiangiogenic13, anti-microbial14 and anti-inflammatory15 drug candidates. Further, heterocyclic hits are of considerable utility in synthetic medicines or pesticides and biochemical effects. Heterocycles containing pyrazole, imidazo[1,2-b]-pyrazole, pyrazolopyrimidine, pyrazolo-triazine scaffolds exhibit versatile biological properties such as anti-inflammatory, antifungal, antioxidant, antitumor and immunosuppressive agents16–26. Hence, molecular hybridization strategy via introduction of different pharmacophoric fragments might improve the biological activity of phthalimide derivatives.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            }
        ],
        [
            {
                "n_rp": 24,
                "xref_id": "CIT0016",
                "rp_string": "16–26",
                "pl_string": "16–26",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),745,244)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 14,
                "xref_id": "",
                "pl_string": "16–26",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),745,244)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 15,
                "xref_id": "",
                "pl_string": "16–26",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),745,244)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 16,
                "xref_id": "",
                "pl_string": "16–26",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),745,244)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 17,
                "xref_id": "",
                "pl_string": "16–26",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),745,244)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 18,
                "xref_id": "",
                "pl_string": "16–26",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),745,244)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 19,
                "xref_id": "",
                "pl_string": "16–26",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),745,244)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 20,
                "xref_id": "",
                "pl_string": "16–26",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),745,244)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 21,
                "xref_id": "",
                "pl_string": "16–26",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),745,244)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 22,
                "xref_id": "",
                "pl_string": "16–26",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),745,244)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 23,
                "xref_id": "",
                "pl_string": "16–26",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),745,244)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 24,
                "xref_id": "CIT0016",
                "rp_string": "16–26",
                "pl_string": "16–26",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),745,244)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 31,
                "xref_id": "CIT0027",
                "rp_string": "27–32",
                "pl_string": "Bearing in mind our program in the synthesis of biologically active heterocyclic compounds27–32 and the molecular pharmacophores (I-V) outlined in Figure 1 and their structural requirements33–36, some phthalimide derivatives were designed after exploring molecular hybridization approaches with pyrazole, imidazo[1,2-b]-pyrazole, pyrazolopyrimidine, pyrazolo-triazine moieties (Figure 1). All the newly prepared phthalimide derivatives were subjected for evaluation of both antimicrobial and anticancer activities with the study of their Drug-Likeness and Toxicity parameters. Furthermore, in-vitro enzyme assay of the most potent derivative was performed against E. coli topoisomerase II DNA gyrase B and VEGFR-2 enzymes, followed by molecular docking studies to get a distinct insight about the interactions and binding mode in the active sites of these enzymes.",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[1]",
                "pl_xpath": "/article/body/sec[1]/p[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,391)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 26,
                "xref_id": "",
                "pl_string": "27–32",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,391)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 27,
                "xref_id": "",
                "pl_string": "27–32",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,391)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 28,
                "xref_id": "",
                "pl_string": "27–32",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,391)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 29,
                "xref_id": "",
                "pl_string": "27–32",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,391)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 30,
                "xref_id": "",
                "pl_string": "27–32",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,391)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 31,
                "xref_id": "CIT0027",
                "rp_string": "27–32",
                "pl_string": "Bearing in mind our program in the synthesis of biologically active heterocyclic compounds27–32 and the molecular pharmacophores (I-V) outlined in Figure 1 and their structural requirements33–36, some phthalimide derivatives were designed after exploring molecular hybridization approaches with pyrazole, imidazo[1,2-b]-pyrazole, pyrazolopyrimidine, pyrazolo-triazine moieties (Figure 1). All the newly prepared phthalimide derivatives were subjected for evaluation of both antimicrobial and anticancer activities with the study of their Drug-Likeness and Toxicity parameters. Furthermore, in-vitro enzyme assay of the most potent derivative was performed against E. coli topoisomerase II DNA gyrase B and VEGFR-2 enzymes, followed by molecular docking studies to get a distinct insight about the interactions and binding mode in the active sites of these enzymes.",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[1]",
                "pl_xpath": "/article/body/sec[1]/p[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,391)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 33,
                "xref_id": "CIT0033",
                "rp_string": "33–36",
                "pl_string": "Bearing in mind our program in the synthesis of biologically active heterocyclic compounds27–32 and the molecular pharmacophores (I-V) outlined in Figure 1 and their structural requirements33–36, some phthalimide derivatives were designed after exploring molecular hybridization approaches with pyrazole, imidazo[1,2-b]-pyrazole, pyrazolopyrimidine, pyrazolo-triazine moieties (Figure 1). All the newly prepared phthalimide derivatives were subjected for evaluation of both antimicrobial and anticancer activities with the study of their Drug-Likeness and Toxicity parameters. Furthermore, in-vitro enzyme assay of the most potent derivative was performed against E. coli topoisomerase II DNA gyrase B and VEGFR-2 enzymes, followed by molecular docking studies to get a distinct insight about the interactions and binding mode in the active sites of these enzymes.",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[3]",
                "pl_xpath": "/article/body/sec[1]/p[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,391)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 33,
                "xref_id": "CIT0033",
                "rp_string": "33–36",
                "pl_string": "Bearing in mind our program in the synthesis of biologically active heterocyclic compounds27–32 and the molecular pharmacophores (I-V) outlined in Figure 1 and their structural requirements33–36, some phthalimide derivatives were designed after exploring molecular hybridization approaches with pyrazole, imidazo[1,2-b]-pyrazole, pyrazolopyrimidine, pyrazolo-triazine moieties (Figure 1). All the newly prepared phthalimide derivatives were subjected for evaluation of both antimicrobial and anticancer activities with the study of their Drug-Likeness and Toxicity parameters. Furthermore, in-vitro enzyme assay of the most potent derivative was performed against E. coli topoisomerase II DNA gyrase B and VEGFR-2 enzymes, followed by molecular docking studies to get a distinct insight about the interactions and binding mode in the active sites of these enzymes.",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[3]",
                "pl_xpath": "/article/body/sec[1]/p[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,391)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 34,
                "xref_id": "",
                "pl_string": "33–36",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,391)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 35,
                "xref_id": "",
                "pl_string": "33–36",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,391)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 36,
                "xref_id": "",
                "pl_string": "33–36",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,391)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 37,
                "xref_id": "CIT0013",
                "rp_string": "13",
                "rp_xpath": "/article/body/sec[2]/sec[2]/sec[2]/p/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[2]/sec[2]/p),161,221)",
                "containers_title": [
                    "Experimental",
                    "General procedure for the synthesis of imidazo[1,2-b]pyrazole derivatives (5–7)",
                    "2-((2-Amino-6-hydroxy-3H-imidazo[1,2-b]pyrazol-7-yl)diazenyl)isoindoline-1,3-dione (6)"
                ]
            }
        ],
        [
            {
                "n_rp": 38,
                "xref_id": "CIT0037",
                "rp_string": "37",
                "rp_xpath": "/article/body/sec[2]/sec[4]/sec[1]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[4]/sec[1]/p),633,111)",
                "containers_title": [
                    "Experimental",
                    "Biological activity",
                    "Antimicrobial activity"
                ]
            }
        ],
        [
            {
                "n_rp": 39,
                "xref_id": "CIT0037",
                "rp_string": "37",
                "rp_xpath": "/article/body/sec[2]/sec[4]/sec[1]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[4]/sec[1]/p),746,201)",
                "containers_title": [
                    "Experimental",
                    "Biological activity",
                    "Antimicrobial activity"
                ]
            }
        ],
        [
            {
                "n_rp": 40,
                "xref_id": "CIT0038",
                "rp_string": "38",
                "rp_xpath": "/article/body/sec[2]/sec[4]/sec[2]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[4]/sec[2]/p),1,293)",
                "containers_title": [
                    "Experimental",
                    "Biological activity",
                    "Antitumor activity"
                ]
            }
        ],
        [
            {
                "n_rp": 41,
                "xref_id": "CIT0040",
                "rp_string": "40",
                "rp_xpath": "/article/body/sec[2]/sec[4]/sec[3]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[4]/sec[3]/p),260,223)",
                "containers_title": [
                    "Experimental",
                    "Biological activity",
                    "In-vitro enzyme assay on DNA gyrase B and VEGFR-2"
                ]
            }
        ],
        [
            {
                "n_rp": 42,
                "xref_id": "CIT0042",
                "rp_string": "42",
                "rp_xpath": "/article/body/sec[2]/sec[5]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[5]/p),129,250)",
                "containers_title": [
                    "Experimental",
                    "In silico calculations of molecular properties"
                ],
                "pl_string": "Molecular descriptors display the pharmacokinetic, pharmacodynamic and physicochemical effects of all synthesized targets 3–17. The lipophilicity (milogP) and topological polar surface area (tPSA) were calculated using the online software Molinspiration42, while the aqueous solubility, drug-likeness, drug score were calculated using the OSIRIS property explorer software43. Furthermore, according to Veber et al., good bioavailability44, is more favorable for targets having TPSA of ≤140 A°2 and ≤10 rotatable bonds. Decreased molecular flexibility, as determined by the rotatable bond number, and low polar surface area or total hydrogen bond count, which are vital predictors of good oral bioavailability, independent of molecular weight.",
                "pl_xpath": "/article/body/sec[2]/sec[5]/p"
            },
            {
                "n_rp": 43,
                "xref_id": "CIT0043",
                "rp_string": "43",
                "rp_xpath": "/article/body/sec[2]/sec[5]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[5]/p),129,250)",
                "containers_title": [
                    "Experimental",
                    "In silico calculations of molecular properties"
                ],
                "pl_string": "Molecular descriptors display the pharmacokinetic, pharmacodynamic and physicochemical effects of all synthesized targets 3–17. The lipophilicity (milogP) and topological polar surface area (tPSA) were calculated using the online software Molinspiration42, while the aqueous solubility, drug-likeness, drug score were calculated using the OSIRIS property explorer software43. Furthermore, according to Veber et al., good bioavailability44, is more favorable for targets having TPSA of ≤140 A°2 and ≤10 rotatable bonds. Decreased molecular flexibility, as determined by the rotatable bond number, and low polar surface area or total hydrogen bond count, which are vital predictors of good oral bioavailability, independent of molecular weight.",
                "pl_xpath": "/article/body/sec[2]/sec[5]/p"
            }
        ],
        [
            {
                "n_rp": 44,
                "xref_id": "CIT0044",
                "rp_string": "44",
                "rp_xpath": "/article/body/sec[2]/sec[5]/p/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[5]/p),381,143)",
                "containers_title": [
                    "Experimental",
                    "In silico calculations of molecular properties"
                ]
            }
        ],
        [
            {
                "n_rp": 45,
                "xref_id": "CIT0045",
                "rp_string": "45",
                "rp_xpath": "/article/body/sec[2]/sec[6]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[6]/p),1,152)",
                "containers_title": [
                    "Experimental",
                    "Molecular modeling study"
                ]
            }
        ],
        [
            {
                "n_rp": 46,
                "xref_id": "CIT0047",
                "rp_string": "47",
                "rp_xpath": "/article/body/sec[2]/sec[6]/p/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[6]/p),155,165)",
                "containers_title": [
                    "Experimental",
                    "Molecular modeling study"
                ]
            }
        ],
        [
            {
                "n_rp": 47,
                "xref_id": "CIT0046",
                "rp_string": "46",
                "rp_xpath": "/article/body/sec[2]/sec[6]/p/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[6]/p),322,195)",
                "containers_title": [
                    "Experimental",
                    "Molecular modeling study"
                ]
            }
        ],
        [
            {
                "n_rp": 48,
                "xref_id": "CIT0048",
                "rp_string": "48",
                "rp_xpath": "/article/body/sec[3]/sec[1]/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[1]/p[1]),100,193)",
                "containers_title": [
                    "Results and discussion",
                    "Chemistry"
                ]
            }
        ],
        [
            {
                "n_rp": 49,
                "xref_id": "CIT0049",
                "rp_string": "49",
                "rp_xpath": "/article/body/sec[3]/sec[1]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[1]/p[1]),295,129)",
                "containers_title": [
                    "Results and discussion",
                    "Chemistry"
                ]
            }
        ],
        [
            {
                "n_rp": 50,
                "xref_id": "CIT0050",
                "rp_string": "50",
                "rp_xpath": "/article/body/sec[3]/sec[1]/p[3]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[1]/p[3]),1,148)",
                "containers_title": [
                    "Results and discussion",
                    "Chemistry"
                ]
            }
        ],
        [
            {
                "n_rp": 51,
                "xref_id": "CIT0051",
                "rp_string": "51",
                "rp_xpath": "/article/body/sec[3]/sec[3]/sec/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[3]/sec/p[1]),197,228)",
                "containers_title": [
                    "Results and discussion",
                    "In silico calculations of molecular properties",
                    "Drug-Likeness parameters:"
                ],
                "pl_xpath": "substring(string(/article/body/sec[3]/sec[3]/sec/p[1]),310,11)",
                "pl_string": "e\n51\n\n,\n\n52"
            },
            {
                "n_rp": 52,
                "xref_id": "CIT0052",
                "rp_string": "52",
                "rp_xpath": "/article/body/sec[3]/sec[3]/sec/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[3]/sec/p[1]),197,228)",
                "containers_title": [
                    "Results and discussion",
                    "In silico calculations of molecular properties",
                    "Drug-Likeness parameters:"
                ],
                "pl_xpath": "substring(string(/article/body/sec[3]/sec[3]/sec/p[1]),310,11)",
                "pl_string": "e\n51\n\n,\n\n52"
            }
        ],
        [
            {
                "n_rp": 53,
                "xref_id": "CIT0044",
                "rp_string": "44",
                "rp_xpath": "/article/body/sec[3]/sec[3]/sec/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[3]/sec/p[1]),702,148)",
                "containers_title": [
                    "Results and discussion",
                    "In silico calculations of molecular properties",
                    "Drug-Likeness parameters:"
                ]
            }
        ],
        [
            {
                "n_rp": 54,
                "xref_id": "CIT0044",
                "rp_string": "44",
                "rp_xpath": "/article/body/sec[3]/sec[3]/sec/p[1]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[3]/sec/p[1]),1240,86)",
                "containers_title": [
                    "Results and discussion",
                    "In silico calculations of molecular properties",
                    "Drug-Likeness parameters:"
                ]
            }
        ],
        [
            {
                "n_rp": 55,
                "xref_id": "CIT0053",
                "rp_string": "53",
                "rp_xpath": "/article/body/sec[3]/sec[3]/sec/p[1]/xref[8]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[3]/sec/p[1]),1554,206)",
                "containers_title": [
                    "Results and discussion",
                    "In silico calculations of molecular properties",
                    "Drug-Likeness parameters:"
                ]
            }
        ],
        [
            {
                "n_rp": 56,
                "xref_id": "CIT0054",
                "rp_string": "54",
                "rp_xpath": "/article/body/sec[3]/sec[3]/sec/p[2]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[3]/sec/p[2]),1177,240)",
                "containers_title": [
                    "Results and discussion",
                    "In silico calculations of molecular properties",
                    "Drug-Likeness parameters:"
                ]
            }
        ],
        [
            {
                "n_rp": 57,
                "xref_id": "CIT0034",
                "rp_string": "34",
                "rp_xpath": "/article/body/sec[3]/sec[4]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[4]/p[1]),1,374)",
                "containers_title": [
                    "Results and discussion",
                    "Molecular modeling study"
                ],
                "pl_string": "Based on the kinase assessment observations and the previous literatures illustrated the important correlation between phthalimide analogs and E. coli topoisomerase II DNA gyrase B as antibacterial target34,35 and VEGFR-2 as anticancer core32, we decided to investigate the possible interactions and binding modes of compound 4 with the active sites of those enzymes. Docking simulations were performed using the X-ray crystallographic structures for DNA gyrase B (PDB ID: 1KZN)44 with the natural inhibitor clorobiocin and for VEGFR-2 (pdb code: 2OH4)45 with the original ligand GIG. The cocrystallized ligands clorobiocin and GIG were redocked into the pocket sites of DNA gyrase B and VEGFR-2 and revealed docking score energies −11.4, −13.7 kcal/mol at RMSD value (root mean square deviation) equal 9.3, 8.5, respectively. The energy is minimized for compound 4 in 3 D picture, and then it saved in a molecular data base (MDB) file to be docked into the active sites of the two enzymes. It showed score energies lower than the co-crystallized ligands (−12.3, −15.6 kcal/mol) with DNA gyrase B and VEGFR-2, respectively.",
                "pl_xpath": "/article/body/sec[3]/sec[4]/p[1]"
            },
            {
                "n_rp": 58,
                "xref_id": "CIT0035",
                "rp_string": "35",
                "rp_xpath": "/article/body/sec[3]/sec[4]/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[4]/p[1]),1,374)",
                "containers_title": [
                    "Results and discussion",
                    "Molecular modeling study"
                ],
                "pl_string": "Based on the kinase assessment observations and the previous literatures illustrated the important correlation between phthalimide analogs and E. coli topoisomerase II DNA gyrase B as antibacterial target34,35 and VEGFR-2 as anticancer core32, we decided to investigate the possible interactions and binding modes of compound 4 with the active sites of those enzymes. Docking simulations were performed using the X-ray crystallographic structures for DNA gyrase B (PDB ID: 1KZN)44 with the natural inhibitor clorobiocin and for VEGFR-2 (pdb code: 2OH4)45 with the original ligand GIG. The cocrystallized ligands clorobiocin and GIG were redocked into the pocket sites of DNA gyrase B and VEGFR-2 and revealed docking score energies −11.4, −13.7 kcal/mol at RMSD value (root mean square deviation) equal 9.3, 8.5, respectively. The energy is minimized for compound 4 in 3 D picture, and then it saved in a molecular data base (MDB) file to be docked into the active sites of the two enzymes. It showed score energies lower than the co-crystallized ligands (−12.3, −15.6 kcal/mol) with DNA gyrase B and VEGFR-2, respectively.",
                "pl_xpath": "/article/body/sec[3]/sec[4]/p[1]"
            },
            {
                "n_rp": 59,
                "xref_id": "CIT0032",
                "rp_string": "32",
                "rp_xpath": "/article/body/sec[3]/sec[4]/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[4]/p[1]),1,374)",
                "containers_title": [
                    "Results and discussion",
                    "Molecular modeling study"
                ],
                "pl_string": "Based on the kinase assessment observations and the previous literatures illustrated the important correlation between phthalimide analogs and E. coli topoisomerase II DNA gyrase B as antibacterial target34,35 and VEGFR-2 as anticancer core32, we decided to investigate the possible interactions and binding modes of compound 4 with the active sites of those enzymes. Docking simulations were performed using the X-ray crystallographic structures for DNA gyrase B (PDB ID: 1KZN)44 with the natural inhibitor clorobiocin and for VEGFR-2 (pdb code: 2OH4)45 with the original ligand GIG. The cocrystallized ligands clorobiocin and GIG were redocked into the pocket sites of DNA gyrase B and VEGFR-2 and revealed docking score energies −11.4, −13.7 kcal/mol at RMSD value (root mean square deviation) equal 9.3, 8.5, respectively. The energy is minimized for compound 4 in 3 D picture, and then it saved in a molecular data base (MDB) file to be docked into the active sites of the two enzymes. It showed score energies lower than the co-crystallized ligands (−12.3, −15.6 kcal/mol) with DNA gyrase B and VEGFR-2, respectively.",
                "pl_xpath": "/article/body/sec[3]/sec[4]/p[1]"
            }
        ],
        [
            {
                "n_rp": 60,
                "xref_id": "CIT0044",
                "rp_string": "44",
                "rp_xpath": "/article/body/sec[3]/sec[4]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[4]/p[1]),377,219)",
                "containers_title": [
                    "Results and discussion",
                    "Molecular modeling study"
                ]
            }
        ]
    ]
}